Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26417680 | 0.79 | ELANE (0.46) | ELANEKMT2AALDH1A1GAARAB9A | |
| SCHEMBL26428676 | 0.73 | TSHR (0.42) | KMT2AALDH1A1GAARAB9ANPC1 | |
| SCHEMBL26428988 | 0.70 | RAB9A (0.46) | ELANEKMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL17355713 | 0.70 | ELANE (0.51) | ELANEKMT2AS1PR3RAB9ANPC1 | |
| SCHEMBL26446040 | 0.69 | SMN1; SMN2 (0.46) | KMT2AALDH1A1GAARAB9ANPC1 | |
| SCHEMBL17356448 | 0.69 | ELANE (0.47) | ELANEGAAMAPTPOLB | |
| SCHEMBL23417965 | 0.68 | KDM4E (0.52) | KMT2AALDH1A1GAARAB9ANPC1 | |
| SCHEMBL29177224 | 0.67 | ALDH1A1 (0.47) | KMT2AALDH1A1GAARAB9ANPC1 | |
| SCHEMBL28238289 | 0.66 | KMT2A (0.53) | KMT2AALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL31742324 | 0.66 | ELANE (0.41) | ELANERXFP1S1PR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | ELANE 1609/4885RXFP1 3878/4885KMT2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.